We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+66.65%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.82B
AUM Growth
-$64.9M
Cap. Flow
+$24.6M
Cap. Flow %
1.35%
Top 10 Hldgs %
65.19%
Holding
53
New
8
Increased
7
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$59.6M
2
JANX icon
Janux Therapeutics
JANX
+$55.5M
3
DRUG
Bright Minds Biosciences
DRUG
+$37.3M
4
OKUR
OnKure Therapeutics
OKUR
+$27.8M
5
BIOA
BioAge Labs
BIOA
+$17.2M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$93M
2
PCVX icon
Vaxcyte
PCVX
+$57.1M
3
BHVN icon
Biohaven
BHVN
+$16.2M
4
URGN icon
UroGen Pharma
URGN
+$15M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
51
Neurogene
NGNE
$712M
– –
-107,344
Closed -$4.5M
SLN
52
Silence Therapeutics
SLN
$564M
– –
-400,000
Closed -$7.27M
LBPH
53
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-2,790,462
Closed -$93M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Cormorant Asset Management held 53 positions worth $1.82B, down 3.4% from $1.89B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Cormorant Asset Management's Q4 2024 filing shows 8 new, 7 increased, 11 reduced and 5 closed positions. Its largest new stake was Bright Minds Biosciences: 1,059,331 shares worth $38.2M. The largest sale was Longboard Pharmaceuticals, Inc. Common Stock, an estimated $93M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Cormorant Asset Management's largest Q4 2024 buy was Bright Minds Biosciences: 1,059,331 shares worth $38.2M.
  • Cormorant Asset Management added most to Praxis Precision Medicines in Q4 2024, an estimated $59.6M increase.
  • Cormorant Asset Management's biggest Q4 2024 reduction was Vaxcyte, cutting an estimated $57.1M.
  • Cormorant Asset Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $93M.
  • Cormorant Asset Management's ten largest holdings make up 65% of its $1.82B portfolio in Q4 2024.
  • Cormorant Asset Management opened 8 new positions and closed 5 in Q4 2024.
  • Cormorant Asset Management's portfolio value fell 3.4% quarter-over-quarter to $1.82B.

Based on Cormorant Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.